Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Sponsor
Haruhiko Fukuda
Study ID
NCT00147121
Phase
PHASE2/PHASE3
Status
Completed

Conditions

  • Lymphoma, B-Cell

Eligibility Criteria

Sex
ALL
Age
20 Years - 69 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma

Key Dates

First listed
Sep 7, 2005
Start date
Sep 30, 2002
Status verified
Sep 2016
Primary completion
Feb 28, 2010
Completion
Feb 28, 2010

Study Design

Enrollment
300 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1
    Rituximab+Standard CHOP
  • Experimental: 2
    Rituximab+bi-Weekly CHOP

Primary Outcome Measure

CR rate (phase II) [ Time Frame: during the study conduct ]

Related Studies